Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Neoplasma Vol.50, p.257-261, 2003 |
||
Title: Prevalence and prognostic value of c-erbB2 expression in non-small cell lung cancer (NSCLC). | ||
Author: O., TURKEN ; E., KUNTER ; H., CERMIK ; T., ISITMANGIL ; G., KANDEMIR ; M., YAYLACI ; A., OZTURK ; | ||
Abstract: The c-erbB2 oncoprotein is highly expressed in approximately one third of
non-small cell lung cancer (NSCLC) patients. We determined the status of c-erbB2
expression in our patients with NSCLC and investigated its correlation with
disease stage, histological type and response to treatment. Eighty-four patients
were examined for the expression of c-erbB2 by immunohistochemistry using a
polyclonal antibody. The scoring criteria of Clinical Trial Assay (CTA) were
used to evaluate staining (0 to +3). c-erbB2 overexpression was determined in
35% of the cases. Tumors from higher stage disease (stage IIIb-IV) were more
often c-erbB2 positive in adenocarcinoma (ADC) (p=0.04). In addition, there was
an association between c-erbB2 score and disease stage in ADC patients (p=0.03).
Our study did not demonstrate an association of c-erbB2 overexpression with
response to chemotherapy. We conclude that c-erbB2 overexpression may be a
prognostic marker for evaluating tumor progression in NSCLC patients but further
studies must be performed with larger patient populations.
|
||
Keywords: | ||
Year: 2003, Volume: 50, Issue: | Page From: 257, Page To: 261 | |
|
download file |
|